Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Tang, Kuo Tung ^a,b   Hung, Wei Ting ^a,c   Chen, Yi Hsing ^a,b   Lin, Ching Heng ^a   Chen, Der Yuan ^a,b,c,d  

^a Taichung Veterans General Hospital   (China)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CHRONIC HEPATITIS B; COHORT ANALYSIS; COMPLICATION; FEMALE; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TAIWAN; TOXIC HEPATITIS; VIROLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHEMICAL AND DRUG INDUCED LIVER INJURY; COHORT STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAIWAN;

EID: 84959577176     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22387     Document Type: Article

References (34)

1. Aithal, G. P. Hepatotoxicity related to antirheumatic drugs. Nat. Rev. Rheumatol. 7, 139-150 (2011).
2. Zachariae, H., Kragballe, K. & Sogaard, H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br. J. Dermatol. 102, 407-412 (1980).
3. Aithal, G. P. et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment. Pharmacol. Ther. 19, 391-399 (2004).
4. Themido, R., Loureiro, M., Pecegueiro, M., Brandao, M. & Campos, M. C. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm. Venereol. 72, 361-364 (1992).
5. Boffa, M. J., Chalmers, R. J., Haboubi, N. Y., Shomaf, M. & Mitchell, D. M. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br. J. Dermatol. 133, 774-778 (1995).
6. Singh, J. A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64, 625-639 (2012).
7. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492-509 (2014).
8. Kremer, J. M., Lee, R. G. & Tolman, K. G. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum. 32, 121-127 (1989).
9. Kremer, J. M., Kaye, G. I., Kaye, N. W., Ishak, K. G. & Axiotis, C. A. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum. 38, 1194-1203 (1995).
10. Aponte, J. & Petrelli, M. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum. 31, 1457-1464 (1988).
11. Rau, R., Karger, T., Herborn, G. & Frenzel, H. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J. Rheumatol. 16, 489-493 (1989).
12. Richard, S., Guerret, S., Gerard, F., Tebib, J. G. & Vignon, E. Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system. Rheumatology (Oxford) 39, 50-54 (2000).
13. Bjorkman, D. J., Boschert, M., Tolman, K. G., Clegg, D. O. & Ward, J. R. The effect of long-term methotrexate therapy on hepatic fibrosis in rheumatoid arthritis. Arthritis Rheum. 36, 1697-1701 (1993).
14. Ros, S. et al. Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Scand. J. Rheumatol. 31, 330-336 (2002).
15. Zachariae, H. Liver biopsies and methotrexate: a time for reconsideration? J Am. Acad. Dermatol. 42, 531-534 (2000).
16. Whiting-O'Keefe, Q. E., Fye, K. H. & Sack, K. D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. 90, 711-716 (1991).
17. Kremer, J. M. et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 37, 316-328 (1994).
18. Heidelbaugh, J. J. & Sherbondy, M. Cirrhosis and chronic liver failure: part II. Complications and treatment. Am. Fam. Physician 74, 767-776 (2006).
19. Merican, I. et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 15, 1356-1361 (2000).
20. Huang, S. W. et al. Osteoarthritis increases the risk of dementia: a nationwide cohort study in Taiwan. Sci. Rep. 5, 10145 (2015).
21. Hung, C. Y. et al. Age and CHADS2 Score Predict the Effectiveness of Renin-Angiotensin System Blockers on Primary Prevention of Atrial Fibrillation. Sci. Rep. 5, 11442 (2015).
22. Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315-324 (1988).
23. Dougados, M. et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 73, 62-68 (2014).
24. Dietrichson, O., From, A., Christoffersen, P. & Juhl, E. Morphological changes in liver biopsies from patients with rheumatoid arthritis. Scand. J. Rheumatol. 5, 65-69 (1976).
25. Rau, R., Pfenninger, K. & Boni, A. Proceedings: Liver function tests and liver biopsies in patients with rheumatoid arthritis. Ann. Rheum. Dis. 34, 198-199 (1975).
26. Huang, Y. W. et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin. Infect. Dis. 57, 1695-1702 (2013).
27. Chen, C. J. & Yang, H. I. Natural history of chronic hepatitis B REVEALed. J. Gastroenterol. Hepatol. 26, 628-638 (2011).
28. Cheng, A. L. et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37, 1320-1328 (2003).
29. Fleming, A., Crown, J. M. & Corbett, M. Prognostic value of early features in rheumatoid disease. Br. Med. J. 1, 1243-1245 (1976).
30. Kaufmann, J., Kielstein, V., Kilian, S., Stein, G. & Hein, G. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J. Rheumatol. 30, 2350-2355 (2003).
31. Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005-2023 (2012).
32. Dawwas, M. F. & Aithal, G. P. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment. Pharmacol. Ther. 40, 938-948 (2014).
33. van den Bemt, B. J., Zwikker, H. E. & van den Ende, C. H. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev. Clin. Immunol. 8, 337-351 (2012).
34. Cheng, W. J., Cheng, Y., Huang, M. C. & Chen, C. J. Alcohol dependence, consumption of alcoholic energy drinks and associated work characteristics in the Taiwan working population. Alcohol Alcohol. 47, 372-379 (2012).